PCRXPacira BioSciences, Inc.
What is the market doing?
In an uptrend. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In an uptrend, above its rising 50- and 200-day averages. Overbought (RSI 86). Price is +52% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PCRX is trading
Pacira BioSciences, Inc. is +54% over the past year while the S&P 500 is +18%: 36 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +52%
vs 200-day average · a clear uptrend
- RSI (14)
- 86
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-08
- $36.41
- 1 monthS&P 500 +1.6%
- +41%
- 1 yearS&P 500 +18%
- +54%
- 5 yearsS&P 500 +86%
- −35%
- vs 50-day average$25.38
- +43%
- 52-week high
- $36.41
- 52-week low
- $19.16
- Annualised volatility
- 51%
| Year | Return |
|---|---|
| 2026 (year to date) | +41% |
| 2025 | +37% |
| 2024 | −44% |
| 2023 | −13% |
| 2022 | −36% |
| 2021 | +0.55% |
| 2020 | +32% |
| 2019 | +5.3% |
| 2018 | −5.8% |
| 2017 | +41% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +2.1% |
| Feb | 10 | 7 of 10 | +1.6% |
| Mar | 10 | 4 of 10 | −1.6% |
| Apr | 10 | 7 of 10 | +5.0% |
| May | 10 | 4 of 10 | −2.2% |
| Jun | 10 | 5 of 10 | +1.4% |
| Jul | 11 | 5 of 11 | −3.1% |
| Aug | 11 | 5 of 11 | +1.5% |
| Sep | 11 | 3 of 11 | −3.6% |
| Oct | 11 | 3 of 11 | −0.68% |
| Nov | 10 | 7 of 10 | +7.6% |
| Dec | 10 | 5 of 10 | +2.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 41 by RyuScore